Enhance MD vs Harper Meds
Two sellers on a four-week cycle, twenty-three dollars apart.
Enhance MD
Editorial
$184/mo
Enhance MD advertises $212 a month for compounded semaglutide on a twelve-month plan, delivered every four weeks, which is thirteen fills a calendar year and $230 a month. The low-dose tirzepatide plan bills $169 twelve times against a forty-eight-week term, or $184 a calendar month. Labs, the consultation and two-day shipping are described as included, and the semaglutide rate is stated as flat at all doses.
Pick it for: Readers comparing the lower of two four-week figures
Harper Meds
Editorial
$161/mo
Harper Meds prices compounded semaglutide at a flat $149 and compounded tirzepatide at a flat $196, with the consultation, the prescription, four weeks of medication and free shipping inside the charge. Both rates are stated as flat at every dose. Four weeks is not a calendar month, so thirteen fills land in a year and the figures ranked here are $161 and $212.
Pick it for: Readers who want the inclusions stated rather than inferred
Our verdict
Both bill on four weeks rather than a calendar month, so both charge thirteen times a year. Harper Meds describes its fill as all-inclusive; Enhance MD does not make that claim.
What actually separates them
Enhance MD and Harper Meds state different things about published price. Everything else they publish, they publish the same way.
Enhance MD costs $23 more than Harper Meds — 14% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,932 at Harper Meds against $2,208 at Enhance MD — a difference of $276.
| Enhance MD | Harper Meds | |
|---|---|---|
| Published price | $184/mo | $161/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.